Netakimab

DRUG4 trials

Sponsors

Pirogov Russian National Research Medical University, Biocad, SPH-BIOCAD (HK) Limited

Conditions

Ankylosing SpondylitisCOVID-19Mild to ModeratePlaque Psoriasis

Phase 3

Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis

Active, not recruitingNCT06640517

BiocadPlaque Psoriasis

Start: 2024-08-08End: 2028-02-29Target: 140Updated: 2025-06-24

To Evaluate the Efficacy and Safety of Netakimab in Chinese Patients With Moderate to Severe Plaque Psoriasis

Active, not recruitingNCT07008547

SPH-BIOCAD (HK) LimitedPlaque Psoriasis

Start: 2024-07-30End: 2026-03-11Updated: 2025-06-06

Evaluate the Efficacy, Safety, and Pharmacokinetic Profile and Immunogenicity of Subcutaneous Netakimab in Chinese Adult Patients With Active Ankylosing Spondylitis

CompletedNCT07277179

SPH-BIOCAD (HK) LimitedAnkylosing Spondylitis

Start: 2023-03-20End: 2025-05-16Updated: 2025-12-11

Unknown Phase

COVID-19 Study at the Russian Clinical and Research Center of Gerontology of the Pirogov RNRMU

CompletedNCT05302947

Pirogov Russian National Research Medical UniversityCOVID-19, Mild to Moderate

Start: 2020-02-01End: 2021-06-30Updated: 2022-04-08